Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors

NCT03552406 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

BIOLOGICAL: ISU104
DRUG: Cetuximab

Sponsor

ISU Abxis Co., Ltd.